HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermatopharmacokinetics may not be appropriate for follicle-targeted topicals -- FDA.

This article was originally published in The Rose Sheet

Executive Summary

DERMATOPHARMACOKINETIC TESTS MAY NOT BE APPROPRIATE FOR FOLLICLE-TARGETED TOPICAL products in the evalua-tion of bioequivalence, FDA's Pharmaceutical Science Advisory Committee suggested in December. "We agree that if there are specific targets to the lower follicle, then the dermatopharmacokinetics may not be appropriate," the committee's acting chair, Cheryl Zimmerman, PhD, University of Minnesota, said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel